Latest Us Market News

Tungsten Mining is pursuing a US stock exchange listing to tap into deeper capital markets and strengthen ties with US government and industry stakeholders, complementing its existing ASX listing.

Artrya Limited reported a 44% increase in its half-year loss to $10.7 million as it transitioned from development to commercial operations in the US, securing FDA clearance and signing three foundation customers. An $80 million capital raise underpins its ambitious US expansion and ongoing product development.

Kip McGrath Education Centres Limited reported a 15.4% rise in profit after tax for the half-year ending December 2025, driven by pricing and operational efficiencies despite a 5% drop in lesson volumes. The company also declared a fully franked interim dividend and completed a share buyback amid leadership changes.

Cyclopharm Limited reported a 17% revenue increase to a record $32.3 million in 2025, powered by a 226% surge in US Technegas sales. The company is accelerating its US rollout with plans for up to 300 installations in 2026, while advancing clinical trials beyond pulmonary embolism.

Compumedics Limited has reported a robust half-year performance, with revenue climbing 32% to $31 million and a return to profitability, driven by strong MEG system sales and SaaS growth.

MyEco Group has reported a 38% improvement in profit before tax and a 51% rise in normalised EBITDA for the first half of FY26, driven by operational restructuring and targeted sales growth. The company’s refreshed leadership team and strategic priorities set the stage for further expansion in sustainable packaging markets.

Epiminder Limited has reported a $21.7 million loss for the half-year ending December 2025, alongside a successful $125 million IPO that fuels its commercialisation of the FDA-approved Minder epilepsy monitoring device.

Imricor Medical Systems saw a sharp 69.5% decline in revenue for 2025, driven by clinical trial impacts, yet narrowed its net loss to $25.3 million as it secured FDA clearance for key products post-year-end.

Orthocell Limited has reported a record half-year revenue of $6.2 million, driven by accelerating sales of its regenerative medicine products and expanding global footprint. The company’s US commercial launch of Remplir™ is gaining momentum alongside new market entries in Canada, Hong Kong, and Europe.

Amaero Ltd has announced plans to re-domicile from Australia to the United States, aiming to tap into larger capital markets and position itself for a potential US IPO by late 2026 or early 2027. The move retains its ASX listing while opening doors to broader investor pools and strategic growth opportunities.

QuickFee Limited has reported a dramatic turnaround with a $36.45 million profit in H1 FY26, driven by the sale of its US Pay Now business and a strategic capital return to shareholders. Underlying operations show promising growth despite divestments.

Singular Health Group reported a 55% rise in net loss to $2.97 million for H1 FY2026, driven by share-based payments and strategic hires, while making significant progress in US commercial deployments and securing FDA clearance for its cloud-based 3D medical imaging platform.